Industries > Pharma > Gene Therapy R&D and Revenue Forecasts 2020-2030

Gene Therapy R&D and Revenue Forecasts 2020-2030

Retroviruses, Lentiviruses, Adenoviruses, Adeno Associated Virus, Herpes Simplex Virus, Poxvirus, Vaccinia Virus, Naked/Plasmid Vectors, Gene Gun, Electroporation, Lipofection, Cancer, Rare Diseases, Cardiovascular Disorders, Ophthalmologic Conditions, Infectious Disease, Neurological Disorders, Diabetes Mellitus

PUBLISHED: 06 March 2020
PAGES: 215
PRODUCT CODE: PHA0717

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE

covid-19

The gene therapy market is projected to grow at a CAGR of 32% in the first half of the forecast period. In 2019, the cancer treatment submarket accounted for 55.8% of the gene therapy drug market. Visiongain estimated that gene therapy for rare diseases will be the driver for market growth in the first half of the forecast period.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand-new 215-page report you will receive 157 charts– all unavailable elsewhere.

The 215-page report provides clear detailed insight into the gene therapy market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Gene Therapy market forecasts from 2020-2030

• This report assesses the approved gene therapy products in the market and gives revenue to 2030

• Provides qualitative analysis and forecast of the submarket by indication for the period 2020-2030:
• Cancer
• Cardiovascular disorders
• Rare diseases
• Ophthalmological diseases
• Infectious Diseases
• Neurological Disorders
• Diabetes Mellitus
• Other therapeutic uses

• Profiles leading companies that will be important in the development of the gene therapy market. For each company, developments and outlooks are discussed and companies covered in this chapter include:
• UniQure
• Biogen
• Bluebird Bio
• Spark Therapeutics
• Applied Genetics Technologies Corporation
• Oxford Biomedica
• GenSight Biologics
• & Other Companies

• Assesses the outlook for the leading gene treatment R&D pipeline for 2019 and discusses technological progress and potential. Profiles appear for gene therapy drug candidates, with revenue forecasts for four leading agents:
• Collategene (AMG0001, AnGes MG/Vical)
• BC-819 (BioCancell)
• BC-821 – BioCancell
• SPK-CHM – Spark Therapeutics
• SPK-FIX – Spark Therapeutics/Pfizer
• SPK-TPP1- Spark Therapeutics
• Lenti-D (Bluebird Bio)
• LentiGlobin (Bluebird Bio)
• VM202-DPN – ViroMed

• Provides qualitative analysis of trends that will affect the gene therapies market, from the perspective of pharmaceutical companies, during the period 2020 to 2030. SWOT analysis is provided and an overview of regulation of the gene therapy market by leading region given.

Gene Therapy R&D and Revenue Forecasts 2020-2030

• Our study discusses factors that influence the market including these:
• Translation of research into marketable products modifying human DNA – gene transfer for therapeutic use, altering the nuclear genome
• Genomic editing technology and other supporting components
• Collaborations to develop and launch gene-based products – acquisitions and licensing deals
• Supporting technologies for human genetic modification, gene replacement and targeted drug delivery
• Gene therapies for ophthalmologic diseases – next-generation medicines
• Regulations in the United States, the European Union and Japan – overcoming technological and medical challenges to pass clinical trials.

Visiongain’s study is intended for anyone requiring commercial analyses for the gene therapy market. You find data, trends and predictions.

Buy our report today Gene Therapy R&D and Revenue Forecasts: Retroviruses, Lentiviruses, Adenoviruses, Adeno Associated Virus, Herpes Simplex Virus, Poxvirus, Vaccinia Virus, Naked/Plasmid Vectors, Gene Gun, Electroporation, Lipofection, Cancer, Rare Diseases, Cardiovascular Disorders, Ophthalmologic Conditions, Infectious Disease, Neurological Disorders, Diabetes Mellitus.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Gene Therapy R&D and Revenue Forecasts 2020-2030


Download sample pages

Complete the form below to download your free sample pages for Gene Therapy R&D and Revenue Forecasts 2020-2030


Latest Pharma news

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2022-2032

The pharma wholesale and distribution market was valued at US$511.80 billion in 2021 and is projected to grow at a CAGR of 7.84% during the forecast period 2022-2032.

29 September 2022

READ

Visiongain Publishes Mesenchymal Stem Cells Market Report 2022-2032

The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.

21 September 2022

READ

Visiongain Publishes Advanced Wound Care Management Market Report 2022-2032

The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.

16 September 2022

READ

Visiongain Publishes Gene Therapy R&D Market Report 2022-2032

The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.

15 September 2022

READ